BioCryst: Rises as Japan approves co's genetic disorder drug

Torii Pharmaceutical Co

22/01/2021 13:09

** Biotech co's  BCRX.O  shares rise 6.4% to $9.71 premarket
    ** Co says Japan's health ministry granted marketing and
manufacturing approval to its oral drug, Orladeyo, to prevent
hereditary angioedema (HAE) attacks in patients aged 12 years
and older  urn:newsml:reuters.com:*:nGNXbVB3Q3
    ** HAE is a genetic condition characterized by recurrent
episodes or "attacks" of severe swelling of the skin and mucous
membranes
    ** Co says Orladeyo is the first and only preventive HAE
medication approved in Japan
    ** Says partner Torii Pharmaceutical Co  4551.T  will launch
drug following successful completion of BCRX's pricing
negotiations with the Japanese National Health Insurance System 
    **  BCRX eligible to receive additional milestone payment of
$15 mln from Torii and tiered royalties of 20%-40% of Japanese
net sales
    ** Drug was approved by the U.S. FDA in Dec; co expects
approval decision in Europe in Q2 2021
    ** Stock rose 22.8% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))